MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters

To control the coronavirus disease 2019 (COVID-19) pandemic and the emergence of different variants of concern (VoCs), novel vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed. In this study, we report the potent immunogenicity and efficacy induced in hamsters b...

ver descrição completa

Detalhes bibliográficos
Autores: Boudewijns, Robbert, Pérez Ramírez, Patricia, Lázaro-Frías, Adrián, Van Looveren, Dominique, Vercruysse, Thomas, Thibaut, Hendrik Jan, Weynand, Birgit, Coelmont, Lotte, Neyts, Johan, Astorgano, David, Montenegro, Dolores, Puentes, Eugenia, Rodríguez, Esteban, Dallmeier, Kai, Esteban, Mariano, García-Arriaza, Juan
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:dnet:digitalcsic_::7be6b23ff5cce88fb654f8c7d79ee385
Acesso em linha:http://hdl.handle.net/10261/264386
Access Level:acceso abierto
Palavra-chave:SARS-CoV-2
COVID-19
MVA vaccine
Spike
Hamsters
Immunogenicity
Efficacy
Descrição
Resumo:To control the coronavirus disease 2019 (COVID-19) pandemic and the emergence of different variants of concern (VoCs), novel vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed. In this study, we report the potent immunogenicity and efficacy induced in hamsters by a vaccine candidate based on a modified vaccinia virus Ankara (MVA) vector expressing a human codon optimized full-length SARS-CoV-2 spike (S) protein (MVA-S). Immunization with one or two doses of MVA-S elicited high titers of S- and receptor-binding domain (RBD)-binding IgG antibodies and neutralizing antibodies against parental SARS-CoV-2 and VoC alpha, beta, gamma, delta, and omicron. After SARS-CoV-2 challenge, MVA-S-vaccinated hamsters showed a significantly strong reduction of viral RNA and infectious virus in the lungs compared to the MVA-WT control group. Moreover, a marked reduction in lung histopathology was also observed in MVA-S-vaccinated hamsters. These results favor the use of MVA-S as a potential vaccine candidate for SARS-CoV-2 in clinical trials.

Registos relacionados